|
|
Volumn 17, Issue 4, 1999, Pages 326-327
|
|
Genentech enlightens other angiogenesis programs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
FIBROBLAST GROWTH FACTOR;
FIBROBLAST GROWTH FACTOR 4;
RECOMBINANT VASCULOTROPIN;
ENDOTHELIAL CELL GROWTH FACTOR;
GROWTH PROMOTOR;
LYMPHOKINE;
RECOMBINANT PROTEIN;
VASCULOTROPIN;
VASCULOTROPIN A;
ANGIOGENESIS;
ARTICLE;
CARDIOVASCULAR DISEASE;
CLINICAL RESEARCH;
CORONARY ARTERY DISEASE;
DRUG DELIVERY SYSTEM;
EXERCISE TOLERANCE;
GENE THERAPY;
PERIPHERAL VASCULAR DISEASE;
PRIORITY JOURNAL;
CLINICAL TRIAL;
HUMAN;
CARDIOVASCULAR DISEASES;
CLINICAL TRIALS;
ENDOTHELIAL GROWTH FACTORS;
GENE THERAPY;
GROWTH SUBSTANCES;
HUMANS;
LYMPHOKINES;
NEOVASCULARIZATION, PHYSIOLOGIC;
RECOMBINANT PROTEINS;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
VASCULAR ENDOTHELIAL GROWTH FACTORS;
|
|
EID: 0032588506
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/7877 Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|